Animal Cell Therapies
- Company typePrivate
- Founded2009
- HeadquartersSan Diego, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Animal Cell Therapies firmographics
Firmographics- Name
- Animal Cell Therapies
- Website
- https://actcells.com
- Company type
- Private
- Founded year
- 2009
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Animal Cell Therapies industry classification
Industry- Product category
- Veterinary Regenerative Medicine
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Veterinary Services (54194)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Stem Cell Therapies (Autologous & Allogeneic) (HLAMANAA)
- akta.pro secondary industries
- Cell & Gene Therapy for Veterinary Regeneration (HLAMANAD), Stem Cell–Based Regenerative Therapies (HLAAAGAA), Clinical Research, Trials & Translational Services (Veterinary Regenerative) (HLAMANAL)
Keywords
Where Animal Cell Therapies is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
Animal Cell Therapies business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Animal Cell Therapies product offering
Product offeringCore offering
Animal Cell Therapies performs research and development of stem cell-based treatments intended for acute and chronic diseases in companion animals. The firm develops regenerative-medicine therapeutic products targeted at veterinary clinical use, addressing conditions such as orthopedic, degenerative, and inflammatory disorders in dogs, cats, and horses. Its work spans the translational pipeline from cell isolation and processing through to commercialization with veterinary practitioners.
Differentiator
Problem solved
Functional benefit
Products and services
- Stem Cell Therapies for Companion Animals Research, development, and provision of stem cell-based treatments for acute and chronic diseases in companion animals (including dogs, cats, and horses). Targeted to veterinary clinics, specialty animal hospitals, and veterinary practitioners seeking regenerative medicine options for orthopedic, degenerative, and inflammatory conditions in pets.
Companies that use Animal Cell Therapies
Customer profileIdeal customer profiles1 record
Animal Cell Therapies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Animal Cell Therapies partnerships and signals
Strategic signalScale indicators1 record
Animal Cell Therapies competitors and assessment
Company assessmentDirect peers
- InGeneron: Regenerative medicine company developing point-of-care autologous stem cell therapies for veterinary (and human) applications, sharing ACT's autologous cell-therapy positioning in the animal health market.
- VetStem Biopharma: Veterinary regenerative medicine pioneer offering autologous stem cell services for dogs, cats, and horses. Closest direct competitor to ACT, named in the source as a competitor in the animal regenerative therapies market.
- Ardent Animal Health: Veterinary regenerative medicine company providing stem cell and platelet-rich plasma therapies to companion-animal practices, directly comparable to ACT's stated focus on stem cell treatments for companion animals.
- MediVet Biologics: Veterinary biologics company focused on regenerative therapies (equine and companion animal) including stem cell kits and clinics — directly comparable product offering to ACT.
- VetCell Therapeutics: Veterinary regenerative medicine provider offering stem cell therapies for companion animals and horses; matches ACT's therapeutic indication footprint.
Emerging players
- Cell Therapy Sciences: Regenerative medicine company exploring cell-based therapies in veterinary indications, broadly comparable modality and stage to ACT.
- Gallant: Veterinary stem cell banking and therapy startup focused on companion animals, analogous target market and modality (stem cell banking/treatments for pets) to ACT.
Broad incumbents
- Zoetis: Largest pure-play animal health company globally, with diagnostics, therapeutics and a growing regenerative/cell therapy footprint. Named in the source as a competitor and poses broad commercial scale advantages over ACT.
Market position
Customer concentration
Animal Cell Therapies social profiles
Digital presenceAnimal Cell Therapies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Animal Cell Therapies leadership team
Management profileNumber of profiles
Profiles4 records
Animal Cell Therapies funding detail
Funding detailFunding overview
Funding rounds5 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Animal Cell Therapies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Animal Cell Therapies
What does Animal Cell Therapies do?
Animal Cell Therapies performs research and development of stem cell-based treatments intended for acute and chronic diseases in companion animals. The firm develops regenerative-medicine therapeutic products targeted at veterinary clinical use, addressing conditions such as orthopedic, degenerative, and inflammatory disorders in dogs, cats, and horses. Its work spans the translational pipeline from cell isolation and processing through to commercialization with veterinary practitioners.
When was Animal Cell Therapies founded?
Animal Cell Therapies was founded in 2009. It employs 1 to 10 people.
Where is Animal Cell Therapies based?
Animal Cell Therapies is headquartered in San Diego, United States, in the North America region.
Who are Animal Cell Therapies's main competitors?
Direct peers on record are InGeneron, VetStem Biopharma, Ardent Animal Health, MediVet Biologics and VetCell Therapeutics. Emerging players are Cell Therapy Sciences and Gallant. Zoetis is listed as a broad incumbent.
Does Animal Cell Therapies have an API?
No public API is recorded for Animal Cell Therapies.
What industry is Animal Cell Therapies in?
Animal Cell Therapies's product category is Veterinary Regenerative Medicine. Its primary akta.pro industry code is HLAMANAA, Stem Cell Therapies (Autologous & Allogeneic), with a secondary code of HLAMANAD, Cell & Gene Therapy for Veterinary Regeneration. Its NAICS code is 325414 and its SIC code is 2836.